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ABSTRACT
Objective: A reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous 
estimation of amlodipine besylate (AD) and valsartan (VAL) in pharmaceutical dosage form, and rosuvastatin (RV) and VAL from the bulk mixture.
Method: Chromatographic separation was performed on RP-C18 column. The optimized unique mobile phase (acetonitrile:water and pH adjusted to 
4.8 with acetic acid) was pumped at a flow rate of 0.8 ml/min in the ratio of 75:25% v/v, and the eluents were monitored at 245 nm.
Results: The assay was performed with tablet and percentage of assay was found to 101.39 for AD and 100.05 for VAL, respectively, and with bulk 
mixture, percentage of assay was found to 99.58 for RV and 100.32 for VAL, respectively. Linearity was obtained in the concentration range of 
1–12 µg/ml for AD, 5–50 µg/mL for VAL, and 2–20 µg/ml for RV. The method was statistically validated and RSD was found to be <2%, indicating high 
degree of accuracy and precision of the proposed RP-HPLC method.
Conclusions: The method suggests usefulness of unique mobile phase during the estimation of two or more multicomponent dosage forms. Due to 
its simplicity, rapidness, high precision, and accuracy, the proposed RP-HPLC method can be applied for simultaneous determination of AD and VAL in 
pharmaceutical dosage form, and RV and VAL in bulk mixture.
Keywords: Amlodipine besylate, Valsartan, Rosuvastatin, Reverse-phase high-performance liquid chromatographic, Chromatograph.
INTRODUCTION
Amlodipine besylate (AD), 2 - [(2-amino ethyl)-methyl]-4-(2 - chloro 
phenyl)-1, 4-dihydro-6 -methyl-3, 5-pyridine dicarboxylic acid 3-ethyl-
5-methyl ester, benzene sulfonate, is a potent dihydrocalcium channel 
blocker [1-5]. Various analytical methods have been reported for 
the assay of AD alone or in combination with other antihypertensive 
agents in pharmaceutical formulations. These include reverse-phase 
high-performance liquid chromatography [6-8], stability-indicating LC 
method [9], HPLC method [10,11], in plasma [12,13], high-performance 
thin-layer chromatography (HPTLC) [14], HPTLC in plasma [15], and 
Ultra-performance liquid chromatography (UPLC) [16] and ultraviolet 
(UV) spectroscopic methods [17-22].
Valsartan (VAL) chemically, N-(1-oxopentyl)-N-[(2’-(1H-tetrazol-5-
yl) (1, 1’-biphenyl)-4-yl) methyl]-L-valine, is a potent angiotensin 
receptor blocker [1-3]. Methods such as HPLC [23-26], in plasma [27], 
bioanalytical method [28], UPLC method [29], and thermogravimetric 
method [30] are reported for estimation of VAL alone or in combination 
with other drugs.
Rosuvastatin (RV) chemically, 7-[4-(4-fluorophenyl)-6-(1-methy-
lethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl] 3, 5-di-
hydroxy-hept-6-enoic acid, is one of the more recently introduced 
statins. Statins are 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase 
inhibitors. The conversion of HMG-CoA to mevalonic acid is especial-
ly important because it is a primary control site for cholesterol bio-
synthesis [1-3]. Methods such as RP-HPLC [31-33], simultaneous UV 
spectrophotometric methods [34,35], in plasma [36], and degradation 
study [37] are reported for estimation of RV alone or in combination 
with other drugs.
The drugs are official in BP [38]. AD, VAL, and RV are official in IP [39]. 
The chemical structures of AMB, VAL, and RV are shown in Fig. 1.
Literature survey revealed that several methods are reported for the 
estimation of AD, VAL, and RV individually as well as AD with VAL and along 
with other antihypertensive drugs. However, the combined determination 
of RV and VAL remains to be investigated. The method is found suitable 
for simultaneous determination of these bicomponents with single mobile 
phase. Ability of unique mobile phase for the estimation of two or more 
formulations is advantageous during analysis which saves time as well 
as provides stable chromatographic conditions. Therefore, an attempt 
has been made to develop a suitable analytical method for simultaneous 
estimation of AM and VAL from their pharmaceutical formulations and 
RV and VAL in bulk mixture. RP-HPLC methods have been widely used 
for routine quality control assessment of drugs due to their accuracy, 
repeatability, selectively, sensitivity, and specificity. We have developed a 
simple, precise, accurate, and specific RP-HPLC method for the simultaneous 
determination of AM and VAL, and RV and VAL with unique mobile 
phase. Analytical method must be validated before use to ensure that the 
method under consideration is capable of giving reproducible and reliable 
results. The proposed HPLC with UV detection method was validated in 
accordance with the International Conference on Harmonization (ICH) 
guidelines [40,41], by assessing its selectivity, linearity, accuracy, precision, 
limit of detection (LOD), and limit of quantitation (LOQ).
METHODS
Instrumentation
Analysis was performed with a Shimadzu (Japan) prominence 
chromatograph equipped with an LC-20 AT solvent delivery system, a 
universal loop injector (Rheodyne 7725) of injection capacity of 20 µl, 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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and an SPD-20A UV-Visible detector set at 245 nm. The equipment 
was controlled by a PC workstation with clarity software. Compounds 
were separated on a Phenomenex Luna C18 column (250 mm×4.6 mm 
i.d., 5-μm particle size) under reversed-phase partition conditions. 
The mobile phase was a 75:25 % (v/v) mixture of acetonitrile:water 
(pH 4.8±0.2, adjusted with acetic acid). The flow rate was 0.8 ml/min 
and the run time was 8 min. Before analysis, both the mobile phase 
and sample solutions were degassed by the use of a sonicator (Labman 
Scientific Instruments, Chennai) and filtered through a 0.2 μm filter (Pall 
Corporation, Mumbai). The identity of the compounds was established 
by comparing the retention times of compounds in the sample solution 
and standard solutions. Chromatography was performed in an ambient 
temperature maintained at 40±1°C. The UV spectrum of AD, RV, and 
VAL for selecting the working wavelength of detection was taken 
using a Shimadzu-1700 Double-beam UV-Visible Spectrophotometer 
(Shimadzu, Kyoto, Japan).
Reagents and chemicals
Pharmaceutically, pure samples of AD and RV from Cure Pharma, Pune, 
and VAL from FDC, Mumbai, were obtained as a gift samples and the 
commercial formulation Amlopres VL tablets: AD – 10 mg and VAL – 
160 mg were procured from local market. HPLC-grade acetonitrile, 
water, and acetic acid (HPLC grade) were obtained from Qualigens India 
Pvt., Ltd., Mumbai, India.
Preparation of stock solution of AD, RV, and VAL
About 10 mg of AD, 20 mg of VAL, and 10 mg of RV were accurately 
weighed and transferred into 50 ml volumetric flasks separately. It was 
dissolved in mobile phase and the volume was made up to 50 ml with 
mobile phase. From this standard stock solution, the aliquots of solution 
were further diluted with mobile phase to obtain standard solution 
with conc. range of 1–12 μg/ml for AD, 5–50 μg/ml for VAL, and 2–20 μg 
for RV. Furthermore, mixed standard solution was prepared simulated 
to marketed pharmaceutical dosage form.
Plot of calibration curve
Calibration curve for each drug was plotted at the concentrations of 
1–12 μg/ml for AD, 2–20 μg/ml for RV, and 5–50 μg/ml for VAL. All 
the standard solutions were filtered through syringe filter and injected 
20 μl solutions each time with Hamilton syringe. The chromatograph 
was read and the peak areas were measured. Peak areas were then 
plotted against their respective concentrations for AD, RV, and VAL. 
From the calibration curve, it was found that all the drugs were linear 
in the concentration range of 1–12 μg/ml, 2–20 μg/ml, and 5–50 μg/ml 
for AD, RV, and VAL, respectively. The calibration graph was used as a 
reference to know quantitatively conc. of unknown solution of dosage 
form.
Statistical parameters – standard regression curve analysis was 
obtained by the use of Microsoft Office Excel software and means, 
standard deviations, and coefficient of variance were calculated.
Assay of tablet formulation and bulk mixture
The 20 tablets of the formulation of AD and VAL were weighed and 
average weight of each tablet was found. Tablets of formulation were 
triturated into a fine powder form with a glass mortar pestle. Tablet 
powder equivalent to 2.5 mg AD and 40 mg of VAL was quantitatively 
transferred into a 50 ml volumetric flask and dissolved in mobile phase 
and volume was made up to 50 ml with mobile phase. The solution was 
sonicated for 15 min, to ensure the uniform and homogenous solution 
of the drug. Further, solution was centrifuged at 500 rpm for 10 min 
and the clear supernatant was collected and filtered through membrane 
syringe filter (pore size 0.45 μm). The aliquots of clear solution were 
further diluted to 10 ml with mobile phase to obtain 16 μg/ml of VAL 
and 1 μg/ml of AD. Each sample solution was injected and the peak 
areas were measured for the determination of AD and VAL in tablet 
formulation.
Similarly, the bulk mixture, 10 mg of RV and 80 mg of VAL, was 
prepared, homogenized and powder equivalent to 2.5 mg of RV and 
80 mg of VAL was weighed and transferred into a 50 ml volumetric 
flask and dissolved in mobile phase and volume was made up to 50 ml 
with mobile phase. The solution was sonicated for 15 min, to ensure the 
uniform and homogenous solution of the drug. The aliquot of solution 
was further diluted to 10 ml with mobile phase to obtain 2 μg/ml of RV 
and 16 μg/ml of VAL. The solution was filtered through syringe filter 
(pore size 0.45 μ) and injected 20 μl with Hamilton syringe. Peak areas 
were measured for the determination of RV and VAL in bulk mixture.
Method validation
The objective of method validation is to demonstrate that the method 
is suitable for its intended purpose as it is stated in the ICH guidelines. 
The method was validated for linearity, precision (repeatability and 
intermediate precision), accuracy, selectivity, and specificity. Accuracy 
was assessed by measuring recovery at three different levels. Precision 
assessed by the measurement of intra- and inter-day precision. In the 
intraday study, the concentrations of all the drugs were calculated 
6 times on the same day at different time intervals. In the interday study, 
the concentrations of the drugs were calculated on 6 different days. 
Selectivity and specificity of the method were assessed by injecting 
solutions containing all the drugs; after chromatography, three sharp 
peaks were obtained for all drugs. LOD and LOQ were measured to 
evaluate the detection and quantitation limits of the method and to 
determine whether these were affected by the presence of impurities. 
They were calculated by the use of the equations LOD = 3.3 σ/S and LOQ 
= 10 σ/S, where σ is the standard deviation of the response and S is the 
slope of the calibration plot.
RESULTS AND DISCUSSION
HPLC method development and optimization
The multicomponent formulations have gained a lot of importance as 
there is greater patient acceptability, increased potency, and decreased 
side effects. AD and VAL are a recent combination in the market used 
for the treatment of hypertension; RV and VAL are combination of 
antilipidemic agent and angiotensin receptor blocker, respectively. This 
work was focused on optimization of the conditions for the simple and 
rapid as well as low cost-effective analysis including a selection of the 
proper column or mobile phase to obtain satisfactory results.
Solvent type, solvent strength (volume fraction of organic solvent(s) in 
the mobile phase and pH of the solution), detection wavelength, and 
flow rate were varied to determine the chromatographic conditions 
giving the best separation. The mobile phase conditions were optimized 
so there was no interference from solvent and excipients. Other criteria, 
for example, time required for analysis, appropriate k range (1 <k<10) 
for eluted peaks, assay sensitivity, solvent noise, and use of the same 
solvent system for extraction of the drugs from the formulations during 
drug analysis were also considered.
Fig. 1 Chemical structure of (a) amlodipine besylate, (b) valsartan, (c) rosuvastatin
cba
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To optimize mobile phase, chromatogram of all these drugs were 
obtained in mobile phase acetonitrile:water in 60:40% v/v, but all drugs 
eluted after 9 min. Then, the proportion of acetonitrile was increased to 
70% and the result was elution of two drugs within 6 min and VAL eluted 
after 8 min found. Furthermore, mobile phase composition was changed 
to methanol:water in proportion 70:30% v/v, the result was distorted 
signals that were not well defined. Addition of 0.5 mL acetic acid for 
adjustment of the pH resulted in good separation and symmetrical peaks.
To determine the appropriate wavelength for simultaneous 
determination of AD and VAL, RV and VAL solutions of these compounds 
in mobile phase were scanned in the range of 200–400 nm. From the 
overlaid UV spectra, suitable wavelength considered for monitoring 
the drugs was 245 nm. Solutions of each substance in the mobile 
phase were also injected directly for HPLC analysis and the responses 
(peak area) were recorded at 245 nm. It was observed that all analytes 
absorbed well at 245 nm, and at this wavelength, there was no 
interference from the mobile phase or baseline disturbance, and it was, 
therefore, concluded that 245 nm was the most appropriate wavelength 
for analysis of drugs with suitable sensitivity.
The optimum mobile phase was, therefore, acetonitrile:water 
(pH 4.8±0.1) in the ratio 75:25 (v/v). Under these experimental 
conditions, sharp peaks were obtained for AD, RV, and VAL at the 
Fig. 2: Optimized chromatogram of amlodipine besylate
Fig. 3: Optimized chromatogram of rosuvastatin calcium
Fig. 4: Optimized chromatogram of valsartan
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retention times 2.41, 4.01, and 5.02 min, respectively. The optimized 
chromatogram of AD, RV, and VAL was obtained and shown in 
(Figs. 2,3 and 4). The resolution (RS) between AD and VAL was 2.49 and 
between RV and VAL was found 5.694.
Method validation
The system suitability parameters such as capacity factor, number of 
theoretical plates, and tailing factor for all the analytes were found within 
the limit, indicating the suitability of the system (Table 1). The values 
obtained for k′ (1 < k′< 10) and RS (>2) showed that these chromatographic 
conditions are appropriate for separation and quantification of all 
compounds. The number of theoretical plates and the tailing factor was 
within the acceptance criteria of >2000 and ≤1.5, respectively, indicating 
good column efficiency and optimum mobile phase composition.
Linearity
Linearity was tested in the concentration range of 1–12 μg/ml for 
AD, 2–20 μg/ml for RV, and 5–50 μg/ml for VAL. The solutions were 
chromatographed 6 times, in accordance with the International Conference 
on Harmonization. Separate calibration plots for AD, RV, and VAL were 
constructed by plotting peak area against the respective concentrations 
and the method was evaluated by determination of the correlation 
coefficient and intercept (Fig. 5), calculated in the corresponding statistical 
study (ANOVA; Z), correlation coefficient r2 values >0.999, and intercepts 
very close to zero confirmed the good linearity of the method. The Z values 
calculated for the calibration plots were obtained in satisfactory range, 
indicating that the variances were not significantly different (Table 2).
Assay
The percentage label claim of tablet formulation was found to 101.39% 
and 100.051% for AD and VAL, and 99.58% and 100.32% for RV and VAL, 
respectively. The chromatogram of the analysis of formulation AD and VAL 
is shown in Fig. 6 and for analysis of bulk mixture RV and VAL is shown 
in Fig. 7. Precision of the method was confirmed by the repeated analysis 
of formulation for 6 times. The percentage coefficient of variation (COV) 
values were found to be 0.6866 and 1.6856 for AD and VAL, and 0.5894 
and 1.1899 for VAL and RV, respectively. The low percentage COV values 
indicated that all the three drugs showed good agreement with the label 
claim ensure the precision of the method shown in Table 3.
Precision
Intraday and interday precision was determined by repeating assay 
3 times on the same day for intraday and on 3 different days for interday 
precision. The intraday precision was studied with standard deviation 
as 1.5820 and 1.1721 for AD and VAL, and 1.6297 and 1.6067 for RV 
and VAL, respectively. The interday precision was also studied with 
standard deviation of 1.7878 and 1.6156 for AD and VAL, and 1.4446 
and 1.2356 for RV and VAL, respectively, tabulated in Table 4.
Table 1: System suitability study results of AD, VAL, and RV
Parameters AD VAL RV
Retention time* 2.412 5.021 4.013
Tailing factor* 1.173 1.121 1.257
Asymmetrical factor* 1.267 1.220 1.328
Number of theoretical plates 7344 14544 9087
Capacity factor* 2.87 4.98 5.694
Resolution 2.398 9.323 5.694
Flow rate ml/min 0.8 ml/min 0.8 ml/min 0.8 ml/min
*Mean of six determinations. AD: Amlodipine besylate, VAL: Valsartan,  
RV: Rosuvastatin
Table 2: Linearity data results of AD, VAL, and RV
Parameters AD VAL RV
Detection wavelength 245 nm 245 nm 245 nm
Beer’s law limit (μg/ml) 1–12 5–50 2–20









Slope (b) 37.823 22.37 45.53
Intercept (a) 0.744 0.575 -0.2971
LOD (μg/mL) 0.0464 0.2077 0.1181
LOQ (μg/mL) 0.1406 0.6294 0.3579
Z value* 0.1891 0.1434 0.0665
*Mean of six determinations. AD: Amlodipine besylate, VAL: Valsartan,  
RV: Rosuvastatin
Fig. 5: Calibration curve of amlodipine besylate, rosuvastatin, and 
valsartan 
Fig. 6 Chromatogram of amlodipine besylate and valsartan from the formulation
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Accuracy
To check the accuracy of the developed methods and to study the 
interference of formulation excipients, analytical recovery experiments 
were carried out as per the ICH guidelines.
The results of the recovery studies and its statistical validation data 
given in Table 4 indicate high accuracy of the proposed method. The 
percentage recovery was found to be in the range of 98.73–102.89% 
for AD and 98.58–103.58% for VAL. The percentage COV values for AD 
and VAL were found to be 2.0142 and 2.1395, respectively. The recovery 
study of RV and VAL was performed and data tabulated in Table 4.
Robustness
As defined by the ICH, the robustness of an analytical procedure 
describes to its capability to remain unaffected by small and deliberate 
variations in method parameters. Robustness was performed by small 
variation in the chromatographic conditions and found to be unaffected 
by small variations such as ±2% variation in volume of mobile phase 
composition, ±0.1 ml/min variation in flow rate of mobile phase, and 
±0.1 variation in pH.
Specificity
The specificity of the HPLC method was ascertained by analyzing standard 
drug and sample solutions. The retention time of AD, RV, and VAL was 
confirmed by comparing the retention time with that of the standard.
CONCLUSIONS
A simple isocratic RP-HPLC method with UV detection has been 
developed for simultaneous determination of AD and VAL, and RV 
and VAL. The method was validated for accuracy, precision, specificity, 
and linearity. The run time is relatively short (8 min), which enables 
Fig. 7: Chromatogram of rosuvastatin and valsartan from the bulk mixture
Table 3: Results of tablet formulations assay




Drug content (%) SD Coeff. of variance (%) Std. error
Form. of AD and VAL AD 10 10.1397 101.397 0.6962 0.6866 0.28030
VAL 160 160.083 100.051 1.6865 1.6856 0.68853
Bulk mixture of RV and VAL RV 10 9.9583 99.583 0.58706 0.5894 0.23969
VAL 80 80.2583 100.32 1.19377 1.1899 0.48578
Form: Formulation, Std: Standard. SD: Standard deviation, AD: Amlodipine besylate, VAL: Valsartan, RV: Rosuvastatin
Table 4: Results of intraday, interday precision, and recovery analysis of the method
S. No. Parameter Level of study Drug name S.D. COV
1 Precision of AD and VAL Intraday precision AD 1.5820 1.5770
VAL 1.1721 1.1708
Interday precision AD 1.78789 1.78110
VAL 1.61566 1.62363
Recovery study of AD and VAL 80% AD 2.71622 2.61676
100% 1.2638 1.26468
120% 2.0012 2.01429
80% VAL 1.09145 1.07576
100% 1.95302 1.93829
120% 2.1772 2.13954
2 Precision of RV and VAL Intraday precision RV 1.6297 1.6190
VAL 1.6067 1.5935
Interday precision RV 1.4446 1.4639
VAL 1.2356 1.2241
Recovery study of RV and VAL 80% RV 1.8841 1.8839
100% 1.4015 1.3861
120% 1.3432 1.3254
80% VAL 2.02218 2.0087
100% 1.7501 1.7236
120% 1.8457 1.8188
SD: Standard deviation, COV: Coefficient of variance, AD: Amlodipine besylate, VAL: Valsartan, RV: Rosuvastatin
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rapid quantification of many samples in routine and quality control 
analysis of tablets. The method also uses a solvent system with the 
same composition as the mobile phase for dissolving and extracting 
drugs from the matrices, thus minimizing noise. Thus, the proposed 
method is rapid, selective, requires a simple sample preparation 
procedure, Moreover, the lower solvent consumption leads to a cost-
effective and represents a good procedure of AD and VAL, and RV and 
VAL determination in bulk and pharmaceutical dosage forms.
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